Rare diseases: natural history studies for drug development – guidance for industry

About this guideline

Adopted by the TGA:  27 February 2023

Overseas publication date:  March 2019 

Categories: FDA | Rare diseases 

TGA annotations:

The general principles of this guideline are adopted. Please note that any references to FDA processes are not applicable in submissions to the TGA.

The TGA will monitor the US FDA status of this draft and will consider if further consultation or annotation is required once it moves to a fully adopted guideline. Further consultation will only occur if the principles are materially altered.

• Where FDA guidelines adopted in Australia include references to US legislation, the requirements contained in the referenced US legislation are not applicable to the evaluation of medicines by the TGA.
• The pdf version of this document was downloaded and saved from the U.S. Food and Drug Administration (U.S. FDA) site on 12 March 2024.

For more information see International scientific guidelines adopted in Australia.